Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx™" or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company’s new Chief Scientific Officer (“CSO”).
SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics Inc. (Nasdaq: CODX) (“Co-Dx™" or the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company’s new Chief Scientific Officer (“CSO”). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on infectious disease diagnostics. Notably, Dr. Poritz played a key role in the growth of BioFire® Diagnostics from 2002-2018, including in the development of the FilmArray® platform, an in vitro diagnostic system that uses a syndromic approach to accurately detect and identify infectious pathogens. He also has numerous patents issued and pending in his name. Dr. Poritz has most recently served as the CSO of Idaho Molecular, the subsidiary acquired by Co-Dx at the end of 2021 and has been actively involved with the development of the Company’s upcoming Co-Dx PCR Home testing platform. “It is with great excitement that we welcome Dr. Poritz to the management team of Co-Dx,” remarked Dwight Egan, Company CEO. “Mark has made many notable contributions to molecular diagnostics in a career that has spanned decades, and we expect the impact he will make in advancing of our vision of increasing the accessibility of state-of-the-art molecular diagnostic solutions will be felt immediately. We also extend our gratitude to our outgoing CSO Jesse Montgomery, PhD, for the contributions he has made to Co-Diagnostics and wish him well in his future endeavors.” Dr. Poritz commented, “I am pleased to be able to bring my years of scientific and industry experience to support the completion and launch of the Company’s exciting new platform, as well as the several other products already in active development and those planned for the future. I truly believe that what Co-Diagnostics is doing is unique and innovative, and I look forward to playing an active role in supporting the Company’s efforts.” About Co-Diagnostics, Inc.: Forward-Looking Statements: View original content:https://www.prnewswire.com/news-releases/co-diagnostics-inc-appoints-dr-mark-poritz-as-new-chief-scientific-officer-301664787.html SOURCE Co-Diagnostics | ||
Company Codes: NASDAQ-SMALL:CODX |